Longeveron (LGVN) presented positive data from its Phase 2a CLEAR MIND trial for Lomecel-B in Alzheimer's disease at AAIC. The FDA granted RMAT and Fast Track designations for Lomecel-B in mild Alzheimer's disease, supporting its therapeutic potential.